12-month randomised controlled trial of ginseng extract for moderate COPD

Shergis, Johannah Linda; Thien, Francis; Worsnop, Christopher; Lin, Lin; Zhang, Anthony Lin; Wu, Lei; Xu, Yinji; Langton, David; Costa, Caterina; Fong, Harry H. S.; Wu, Darong; Story, D. F.; Xue, Charlie Changli

doi:10.1136/thoraxjnl-2018-212665

Cited by 14 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main results of this study are similar to our previous clinical trial of Panax ginseng for moderate COPD. 22 In the previous study, ginseng was administered at a lower dose in people with more moderate COPD, and quality of life was the primary outcome. Therefore, this is the first randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of standardized Panax ginseng extract for moderate to very severe stable COPD.…”

Section: Discussionmentioning

confidence: 99%

<p>Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial</p>

Chen¹,

Lin²,

Wu³

et al. 2020

COPD

Self Cite

View full text Add to dashboard Cite

Herbal medicines are commonly used by people with chronic obstructive pulmonary disease (COPD) but high quality randomized controlled trials are limited. This study evaluated the therapeutic value of ginseng capsules in reducing acute exacerbations and improving the quality of life in people with COPD. Patients and Methods: This randomized, double-blind and placebo-controlled trial assessed ginseng's effects on 200 patients with moderate to very severe COPD. Ginseng capsules (200 mg, twice per day) were compared to placebo over 24 weeks. Patients were followed up for a further 24 weeks after the treatment period. The primary outcome measure was acute COPD exacerbation rate over 12 months. Secondary outcome measures were health-related quality of life, including the St George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT) and the Short Form 36 Health Survey (SF-36). We also assessed lung function, walking distance and use of relief medication. Results: Baseline characteristics were balanced between groups. The rate of COPD exacerbations was not statistically significant between groups after 1 year (62 participants in the ginseng group and 63 in the placebo group). Secondary outcome measures showed improvements after ginseng and placebo but results were not clinically significant. The incidence of adverse events in the two groups was similar and events were unrelated to the intervention. Conclusion: Compared with placebo, ginseng did not reduce the rate of acute COPD exacerbations over 12 months. It was safe and well tolerated by people with moderate to very severe COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial</p>

Chen¹,

Lin²,

Wu³

et al. 2020

COPD

Self Cite

View full text Add to dashboard Cite

show abstract

“…Panax ginseng is a therapeutic herb with potential benefits for patients with COPD (13). Recently, Shergis et al (14) reported results from a 12-month randomized controlled trial of ginseng extract for treatment of moderate COPD. The primary endpoints of their study were scores on the St George's Respiratory Questionnaire (15), the COPD Assessment Test (16) and the Short Form Health Survey (17).…”

Section: Discussionmentioning

confidence: 99%

“…To the best of our knowledge, this is the first case report showing long-term maintenance of body weight and nutritional status with ninjinyoueito in terminal patients with chronic respiratory diseases. Ninjinyoueito is becoming an increasingly commonly prescribed medication for patients with chronic respiratory disease such as COPD (3,14,18). Although the underlying mechanism by which ninjinyoueito counteracts weight loss and induces maintenance of nutritional status remains unclear, this Kampo medicine may be used as a supplementary treatment for terminal patients with respiratory diseases.…”

Section: Discussionmentioning

confidence: 99%

Long‑term maintenance of nutritional status with ninjinyoueito in terminal patients with chronic respiratory disease: Two case reports

et al. 2019

View full text Add to dashboard Cite

Ninjinyoeito, is a traditional herbal (Kampo) medicine which is administered to patients with debilitating diseases in NorthEast Asia. Ninjinyoeito has been reported to be effective against loss of physical strength, fatigue and loss of appetite in patients with wasting diseases. The present study described long-term maintenance of body weight with ninjinyoueito in 2 terminal patients with chronic respiratory diseases. The first patient was a 75-year-old with chronic obstructive pulmonary disease (COPD) who took ninjinyoueito for ≥5 years and the second patient was a 72-year-old man with metastatic lung cancer with combined pulmonary fibrosis and emphysema (CPFE) who took ninjinyoueito for ≥1 year. Both of them maintained their physique and nutritional status during the terminal stages of disease and there were no adverse effects observed in these 2 patients which could be attributed to ninjinyoueito. The results suggest that ninjinyoueito may be a supplementary treatment for the maintenance of nutritional status in patients with a chronic respiratory disease accompanied by wasting, such as COPD.

show abstract

“… 17 , 18 Multiple centers involved in randomized controlled trials have explored the clinical effects of the Chinese herbal formula, Yu Ping Feng granules and the single herb Ginseng for the treatment of COPD. 19 , 20 The medical effects of CM therapies have been validated in an increasing number of clinical trials, to satisfy the need for evidence-based medicine. In addition to the evidence of therapeutic interventions, patient beliefs and preferences are powerful influences on the treatment effects in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Chinese Medicine for Chronic Obstructive Pulmonary Disease: A Pilot Study on Patient Preferences

Liu

Lai

et al. 2021

PPA

Self Cite

View full text Add to dashboard Cite

The patient's preference plays an important role in clinical practice. There currently is no available evidence regarding the perception and attitudes of patients with chronic obstructive pulmonary disease (COPD) towards the use of Chinese medicine (CM) approaches. This study was designed to explore preferences and factors associated with CM among COPD patients. Patients and Methods: A pilot survey was conducted among COPD patients using a structured, pre-tested questionnaire. The perceptions of CM therapies (including herbal medicine, non-pharmacotherapies), and expected clinical outcomes were investigated based on patient preference. Factors associated with preference of treatment scenarios were estimated in order of importance. Results: Thirty patients were enrolled in the survey, including 27 males and 3 females. Twothirds of the patients preferred integrative Chinese and Western medicine for the treatment of COPD. Chinese patent medicines and CM decoction therapy were more popular than CM injections. The preferred non-drug therapy was point application, followed by acupuncture, Tai chi, or Qigong. More than 70% of patients reported that important clinical outcomes were improvements in lung function (77%) and dyspnea, cough, and sputum symptoms (73%), followed by exercise endurance (50%). Besides clinical efficacy, costs and side effects were also important factors for treatment selection. Conclusion: This pilot study showed that Chinese patent medicine and CM decoctions were preferred options for complementary medicines to combine with routine pharmacotherapy for COPD treatment according to the patients' preferences. The improvement of dyspnea, cough symptoms, and lung function was the most desired clinical outcomes for patients. Quicker symptom relief, lower costs, and fewer side effects were key attributes for the treatment selection. Further research with a larger sample size is needed to definitively address the comprehensive conclusion.

show abstract

12-month randomised controlled trial of ginseng extract for moderate COPD

Cited by 14 publications

References 19 publications

<p>Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial</p>

<p>Effect of Panax Ginseng (G115) Capsules versus Placebo on Acute Exacerbations in Patients with Moderate to Very Severe COPD: A Randomized Controlled Trial</p>

Long‑term maintenance of nutritional status with ninjinyoueito in terminal patients with chronic respiratory disease: Two case reports

Chinese Medicine for Chronic Obstructive Pulmonary Disease: A Pilot Study on Patient Preferences

Contact Info

Product

Resources

About